Gut microbiome in chronic kidney disease: challenges and opportunities

详细信息    查看全文

• 作者：Anitha Nallu ; Shailendra Sharma ; Ali Ramezani ; Jagadeesan Muralidharan ; Dominic Raj ; ^{draj@mfa.gwu.edu}
• 关键词：CKD ; chronic kidney disease ; ESRD ; end-stage renal disease ; PSA ; polysaccharides ; CVD ; cardiovascular disease ; IS ; indoxyl sulfate ; TMAO ; trimethylamine-N-oxide ; SCFA ; short chain fatty acid ; PCS ; p-cresol sulfate ; Tregs ; regulatory T cells ; IRI ; ischemia and reperfusion injury ; DMB ; 3-dimethyl-1-butanol
• 刊名：Translational Research
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：179
• 期：Complete
• 页码：24-37
• 全文大小：873 K
• 卷排序：179

文摘

More than 100 trillion microbial cells that reside in the human gut heavily influence nutrition, metabolism, and immune function of the host. Gut dysbiosis, seen commonly in patients with chronic kidney disease (CKD), results from qualitative and quantitative changes in host microbiome profile and disruption of gut barrier function. Alterations in gut microbiota and a myriad of host responses have been implicated in progression of CKD, increased cardiovascular risk, uremic toxicity, and inflammation. We present a discussion of dysbiosis, various uremic toxins produced from dysbiotic gut microbiome, and their roles in CKD progression and complications. We also review the gut microbiome in renal transplant, highlighting the role of commensal microbes in alteration of immune responses to transplantation, and conclude with therapeutic interventions that aim to restore intestinal dysbiosis.